From mice to humans – murine intelligence for human CD8⁺ T cell vaccine design

Bibliography

• EHRETH J: The value of vaccination: a global perspective. Vaccine (2003) 21(27-30):4105–4117.
   PubMed Web of Science ®Google Scholar
• BISHAI D, KOENIG M, ALI KHAN M: Measles vaccination improves the equity of health outcomes: evidence from Bangladesh. Health Econ. (2003) 12(5):415–419.
   PubMed Web of Science ®Google Scholar
• LATTANZI M, RAPPUOLI R: Long-term solutions for the problem of vaccine shortages. Expert Opin. Biol. Ther. (2004) 4(6):989–992.
   PubMed Web of Science ®Google Scholar
• BELARDELLI F, FERRANTINI M, PARMIANI G, SCHLOM J, GARACI E: International meeting on cancer vaccines: how can we enhance efficacy of therapeutic vaccines? Cancer Res. (2004) 64(18):6827–6830.
   Google Scholar
• BOT A, VON HERRATH M: Prophylaxis of autoimmune diabetes by antigen based immune modulation: are we there yet? Minerva Med. (2004) 95(2):105–114.
   Google Scholar
• HASSANI M, PATEL MC, PIROFSKI LA: Vaccines for the prevention of diseases caused by potential bioweapons. Clin. Immunol (2004) 111(1):1–15.
   PubMed Web of Science ®Google Scholar
• TRUCKENMILLER ME, NORBURY CC: Viral vectors for inducing CD8* T cell responses. Expert Opin. Biol. Ther. (2004) 4(6):861–868.
   PubMed Web of Science ®Google Scholar
• SIEMENS DR, ELZEY BD, LUBAROFF DM et al.: Cutting edge: restoration of the ability to generate CTL in mice immune to adenovirus by delivery of virus in a collagen-based matrix. J. Immunol. (2001) 166(2):731–735.
   PubMed Web of Science ®Google Scholar
• JUILLARD V, VILLEFROY P, GODFRIN D et al.: Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector. Eur. Immunol (1995) 25(12):3467–3473.
   PubMed Web of Science ®Google Scholar
• BROSSART P, GOLDRATH A. BUTZ E, MARTIN S, BE VAN M: Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. j Immunol (1997) 158(7):3270–3276.
   PubMed Web of Science ®Google Scholar
• HOFMANN C, LOSER P, CICHON G et al.: Ovine adenovirus vectors overcome preexisting humoral immunity against human adenoviruses in vivo. J. Wrol. (1999) 73(8):6930–6936.
   Google Scholar
• FARINA SF, GAO GP, XIANG ZQ et a/.: Replication-defective vector based on a chimpanzee adenovirus. j Wrol. (2001) 75(23):11603–11613.
   Google Scholar
• PAOLETTI E: Applications of pox virus vectors to vaccination: an update. Proc. Natl. Acad. Sci. USA (1996) 93(21):11349–11353.
   PubMed Web of Science ®Google Scholar
• BASAK SK, KIERTSCHER SM, HARUI k ROTH MD: Modifying adenoviral vectors for use as gene-based cancer vaccines. Vita/ immune/. (2004) 17(2):182–196.
   Web of Science ®Google Scholar
• BELYAKOV IM, MOSS B, STROBER W, BERZOFSKY JA: Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. Proc. Natl Acad. Sci. USA (1999) 96(8):4512–4517.
   PubMed Web of Science ®Google Scholar
• YEWDELL JW, BENNINK JR: Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu. Rev. Immunol (1999) 17:51–88.
   PubMed Web of Science ®Google Scholar
• HARRINGTON LE, VAN DER MOST R, WHITTON JL, AHMED R: Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope. j Wrol. (2002) 76(7):3329–3337.
   Google Scholar
• •Uses a vaccinia virus-based vaccine and directly compares the vast antivector responses with the modest recombinant antigen response.
   Google Scholar
• CHEN W, ANTON LC, BENNINK JR, YEWDELL Pci: Dissecting the multifactorial causes of immunodominance in class I-restricted T cell responses to viruses. Immunity (2000) 12(1):83–93.
   PubMed Web of Science ®Google Scholar
• HARVEY TJ, ANRAKU I, LINEDALE R et al.: Kunjin virus replicon vectors for human immunodeficiency virus vaccine development. J. Virol. (2003) 77(107796–7803.
   Web of Science ®Google Scholar
• KOCHANEK S, SCHIEDNER G, VOLPERS C: High-capacity 'gutless' adenoviral vectors. Curr. Opin. Mol. Ther. (2001) 3(5):454–463.
   PubMed Web of Science ®Google Scholar
• OPHORST OJ, KOSTENSE S, GOUDSMIT J et al.: An adenoviral type 5 vector carrying a type 35 fiber as a vaccine vehicle: DC targeting, cross neutralization, and immunogenicity. Vaccine (2004) 22(23-24):3035–3044.
   PubMed Web of Science ®Google Scholar
• NELSON EL, PRIETO D, ALEXANDER TG et al.: Venezuelan equine encephalitis replicon immunization overcomes intrinsic tolerance and elicits effective anti-tumor immunity to the 'self' tumor-associated antigen, neu in a rat mammary tumor model. Breast Cancer Res. Treat. (2003) 82(3):169–183.
   PubMed Web of Science ®Google Scholar
• LUNDSTROM K: Alphavirus vectors for vaccine production and gene therapy. Expert Rev. Vaccines (2003) 2(3):447–459.
   PubMedGoogle Scholar
• DI NICOLA M, CARLO-STELLA C, MORTARINI R et al.: Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34*-derived dendritic cell vaccination: a Phase I trial in metastatic melanoma. Clin. Cancer Res. (2004) 10(16):5381–5390.
   PubMed Web of Science ®Google Scholar
• VAN BROEKHOVEN CL, PARISH CR, DEMANGEL C, BRITTON WJ, ALTIN JG: Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy. Cancer Res. (2004) 64(12):4357–4365.
   PubMed Web of Science ®Google Scholar
• LITTLE SR, LYNN DM, GE Q et al.: Poly-beta amino ester-containing microparticles enhance the activity of nonviral genetic vaccines. Proc. Natl Acad. Sci. USA (2004) 101(26):9534–9539.
   PubMed Web of Science ®Google Scholar
• EBENSEN T, PAUKNER S, LINK C et al.: Bacterial ghosts are an efficient delivery system for DNA vaccines. J. Immunol (2004) 172(11):6858–6865.
   PubMed Web of Science ®Google Scholar
• CURIEL TJ, MORRIS C, BRUMLIK M et al.: Peptides identified through phage display direct immunogenic antigen to dendritic cells. J. Immunol (2004) 172(12):7425–7431.
   PubMed Web of Science ®Google Scholar
• JACKSON DC, LAU YF, LET et al: A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc. Nail. Acad. Sci. USA (2004) 101(43):15440–15445.
   PubMed Web of Science ®Google Scholar
• HEATH WR, BELZ GT, BEHRENS GM et al.: Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol. Rev. (2004) 199:9–26.
   PubMed Web of Science ®Google Scholar
• ALLAN RS, SMITH CM, BELZ GT et al: Epidermal viral immunity induced by CD8ct* dendritic cells but not by Langerhans cells. Science (2003) 301(5640:1925–1928.
   PubMed Web of Science ®Google Scholar
• SCHNARE M, BARTON GM, HOLT AC et al.: Toll-like receptors control activation of adaptive immune responses. Nat. Immunol (2001) 2(10):947–950.
   PubMed Web of Science ®Google Scholar
• JANEWAY CA JR, MEDZHITOV R: Innate immune recognition. Annu. Rev. Immunol (2002) 20:197–216.
   PubMed Web of Science ®Google Scholar
• ••Comprehensive review of TLRs.
   Google Scholar
• KENSIL CR, MO AX, TRUNEH A: Current vaccine adjuvants: an overview of a diverse class. Front. Biosci. (2004) 9:2972–2988.
   PubMed Web of Science ®Google Scholar
• BALDRIDGE JR, MCGOWAN P, EVANS JT et al.: Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opin. Biol. Ther. (2004) 4(7):1129–1138.
   PubMed Web of Science ®Google Scholar
• ISHII KJ, GURSEL I, GURSEL M, KLINMAN DM: Immunotherapeutic utility of stimulatory and suppressive oligodeoxynucleotides. Curr. Opin. Mol. Ther. (2004) 6(2):166–174.
   PubMed Web of Science ®Google Scholar
• KLINMAN DM, CURRIE D, GURSEL I, VERTHELYI D: Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol Rev. (2004) 199:201–216.
   PubMed Web of Science ®Google Scholar
• SHACKLETON M, DAVIS ID, HOPKINS Wet al.: The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant F1t3 ligand. Cancer Immun. (2004) 4:9.
   Google Scholar
• LEITNER WW, HWANG LN, DEVEER MJ et al.: Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat. Med. (2003) 9(1):33–39.
   PubMed Web of Science ®Google Scholar
• CROZAT K, BEUTLER B: TLR7: a new sensor of viral infection. Proc. Natl Acad. Sci. USA (2004) 101(18):6835–6836.
   PubMed Web of Science ®Google Scholar
• TAKEDA K, AKIRA S: TLR signaling pathways. Semin. Immunol. (2004) 16(1):3–9.
   PubMed Web of Science ®Google Scholar
• AGRAWAL S, AGRAWAL A, DOUGHTY B et al.: Cutting edge: different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos. J. Immunol (2003) 171(10):4984–4989.
   PubMed Web of Science ®Google Scholar
• TRIANTAFILOU M, TRIANTAFILOU K: Sepsis: molecular mechanisms underlying lipopolysaccharide recognition. Expert Rev. Mol. Med. (2004) 2004:1–18.
   Google Scholar
• TRIANTAFILOU M, BRANDENBURG K, KUSUMOTO S et al.: Combinational clustering of receptors following stimulation by bacterial products determines lipopolysaccharide responses. Biochem. J. (2004) 381(Pt 2):527–536.
   PubMedGoogle Scholar
• SPIES B, HOCHREIN H, VABULAS M et al.: Vaccination with plasmid DNA activates dendritic cells via Toll-like receptor 9 (TLR9) but functions in TLR9-deficient mice/ Immunol. (2003) 171(11):5908–5912.
   Google Scholar
• BABIUK S, MOOKHERJEE N, PONTAROLLO R et al.: TLR9-/- and TLR9*/* mice display similar immune responses to a DNA vaccine. Immunology (2004) 113(1):114–120.
   PubMed Web of Science ®Google Scholar
• OH S, PERERA LP, BURKE DS, WALDMANN TA, BERZOFSKY JA: IL-15/IL-15Ra-mediated avidity maturation of memory CD8* T cells. Proc. Natl Acad. Sci. USA (2004) 101(42):15154–15159.
   PubMed Web of Science ®Google Scholar
• KWISSA M, KROGER A, HAUSER H, REIMANN J, SCHIRMBECK R: Cytokine-facilitated priming of CD8* T cell responses by DNA vaccination. J. Mol. Med. (2003) 81(2):91–101.
   PubMed Web of Science ®Google Scholar
• PASARE C, MEDZHITOV R: Toll pathway-dependent blockade of CD4*CD25* T cell-mediated suppression by dendritic cells. Science (2003) 299(5609):1033–1036.
   PubMed Web of Science ®Google Scholar
• ORABONA C, GROHMANN U, BELLADONNA ML et al.: CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86. Nat. Immunol (2004) 5(11):1134–1142.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI C, MITTLER RS, VELLA AT: Cutting Edge: 4-1BB is a bona fide CD8 T cell survival signal. J. Immunol (1999) 162(9):5037–5040.
   PubMed Web of Science ®Google Scholar
• FUJII S, LIU K, SMITH C, BONITO AJ, STEINMAN RM: The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J. Exp. Med. (2004) 199(12):1607–1618.
   PubMed Web of Science ®Google Scholar
• SILK JD, HERMANS IF, GILEADI U et al.: Utilizing the adjuvant properties of CD id-dependentNK T cells in T cell-mediated immunotherapy. j Clin. Invest. (2004) 114(12):1800–1811.
   PubMed Web of Science ®Google Scholar
• •Explores the use of an adjuvant that targets natural killer T cells.
   Google Scholar
• GONZALEZ-ASEGUINOLAZA G, VAN KAER L, BERGMANN CC et al: Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines. J. Exp. Med. (2002) 195(5):617–624.
   PubMed Web of Science ®Google Scholar
• GIACCONE G, PUNT CJ, ANDO Y et al.: A Phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin. Cancer Res. (2002) 8(12):3702–3709.
   PubMed Web of Science ®Google Scholar
• BEVAN MJ: Helping the CD8* T-cell response. Nat. Rev. Immunol (2004) 4(8):595–602.
   PubMed Web of Science ®Google Scholar
• ••Review highlighting the recentdebate about the requirement for CD4* T cell help.
   Google Scholar
• NORTHROP JK, SHEN H: CD8* T-cell memory: only the good ones last. Curr. Opin. Immunol (2004) 16(4):451–455.
   PubMed Web of Science ®Google Scholar
• AHONEN CL, DOXSEE CL, MCGURRAN SM et al: Combined TLR and CD40 triggering induces potent CD8* T cell expansion with variable dependence on type I IFN. J. Exp. Med. (2004) 199(0:775–784.
   PubMed Web of Science ®Google Scholar
• •Shows that TLR triggering and CD40 ligation act in synergy, indicating that TLR signalling and CD4* T cell help are not redundant.
   Google Scholar
• SUN JC, BEVAN MJ: Defective CD8 T cell memory following acute infection without CD4 T cell help. Science (2003) 300(5617):339–342.
   PubMed Web of Science ®Google Scholar
• SHEDLOCK DJ, SHEN H: Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science (2003) 300(5617):337–339.
   PubMed Web of Science ®Google Scholar
• JANSSEN EM, LEMMENS EE, WOLFE T et al.: CD4* T cells are required for secondary expansion and memory in CD8* T lymphocytes. Nature (2003) 421(6925):852–856.
   PubMed Web of Science ®Google Scholar
• SUN JC, WILLIAMS MA, BEVAN MJ: CD4* T cells are required for the maintenance, not programming, of memory CD8* T cells after acute infection. Nat. Immunol (2004) 5(9):927–933.
   PubMed Web of Science ®Google Scholar
• HAMILTON SE, PRLIC M, JAMESON SC: Environmental conservation: bystander CD4 T cells keep CD8 memories fresh. Nat. Immunol (2004) 5(9):873–874.
   PubMed Web of Science ®Google Scholar
• BEHRENS GM, LI M, DAVEY GM et al.: Helper requirements for generation of effector CTL to islet 13 cell antigens. J. Immunol. (2004) 172(9):5420–5426.
   PubMed Web of Science ®Google Scholar
• GAO FG, KHAMMANIVONG V, LIU WJ et al.: Antigen-specific CD4* T-cell help is required to activate a memory CD8* T cell to a fully functional tumor killer cell. Cancer Res. (2002) 62(22):6438–6441.
   PubMed Web of Science ®Google Scholar
• SMITH CM, WILSON NS, WAITHMAN Jet al.: Cognate CD4*T cell licensing of dendritic cells in CD8* T cell immunity. Nat. Immunol. (2004) 5(11):1143–1148.
   Google Scholar
• SAKAGUCHI S: Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol (2004) 22:531–562.
   PubMed Web of Science ®Google Scholar
• SHEVACH EM: CD4* CD25* suppressor T cells: more questions than answers. Nat. Rev. Immunol (2002) 2(6):389–400.
   PubMed Web of Science ®Google Scholar
• PICCIRILLO CA, SHEVACH EM: Naturally-occurring CD4*CD25* immunoregulatory T cells: central players in the arena of peripheral tolerance. Semin. Immunol (2004) 16(2):81–88.
   PubMed Web of Science ®Google Scholar
• WALKER LS: CD4* CD25* Treg: divide and rule? Immunology (2004) 111(2):129–137.
   PubMed Web of Science ®Google Scholar
• MILLS KH, MCGUIRK P: Antigen-specific regulatory T cells-their induction and role in infection. Semin. Immunol (2004) 16(2):107–117.
   PubMed Web of Science ®Google Scholar
• SHIMIZU J, YAMAZAKI S, SAKAGUCHI S: Induction of tumor immunity by removing CD25*CD4* T cells: a common basis between tumor immunity and autoimmunity. j Immunol (1999) 163(10):5211–5218.
   PubMed Web of Science ®Google Scholar
• ONIZUKA S, TAWARA I, SHIMIZU J et al: Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor a) monoclonal antibody. Cancer Res. (1999) 59(13):3128–3133.
   PubMed Web of Science ®Google Scholar
• HISAEDA H, MAEKAWA Y, IWAKAWA D et al.: Escape of malaria parasites from host immunity requires CD4*CD25* regulatory T cells. Nat. Med. (2004) 10(1):29–30.
   PubMed Web of Science ®Google Scholar
• SUVAS S, KUMARAGURU U, PACK CD, LEES, ROUSE BT: CD4*CD25* T cells regulate virus-specific primary and memory CD8* T cell responses. J. Exp. Med. (2003) 198(6):889–901.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI T, TAGAMI T, YAMAZAKI S et al: Immunologic self-tolerance maintained by CD25*CD4* regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med. (2000) 192(2):303–310.
   PubMed Web of Science ®Google Scholar
• SHIMIZU J, YAMAZAKI S, TAKAHASHI T, ISHIDA Y, SAKAGUCHI S: Stimulation of CD25*CD4* regulatory T cells through GITR breaks immunological self-tolerance. Nat. Immunol. (2002) 3(2):135–142.
   PubMed Web of Science ®Google Scholar
• MCHUGH RS, WHITTERS MJ, PICCIRILLO CA et al: CD4*CD25* immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity (2002) 16(2):311–323.
   PubMed Web of Science ®Google Scholar
• KHANNA k MORELLI AE, ZHONG C et al: Effects of liver-derived dendritic cell progenitors on Thl- and Th2-like cytokine responses in vitro and in vivo. J. Immunol (2000) 164(3):1346–1354.
   PubMed Web of Science ®Google Scholar
• LAVELLE EC, MCNEELA E, ARMSTRONG ME et al: Cholera toxin promotes the induction of regulatory T cells specific for bystander antigens by modulating dendritic cell activation. Immunol (2003) 171(5):2384–2392.
   Web of Science ®Google Scholar
• MCGUIRK P, MCCANN C, MILLS KH: Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: a novel strategy for evasion of protective T helper type 1 responses by Bordetella pertussis. J. Exp. Med. (2002) 195(2):221–231.
   PubMed Web of Science ®Google Scholar
• BELKAID Y, PICCIRILLO CA, MENDEZ S, SHEVACH EM, SACKS DL: CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature (2002) 420(6915):502–507.
   PubMed Web of Science ®Google Scholar
• •Shows the important role of T,eg in parasite persistence.
   Google Scholar
• SHEVACH EM: Fatal attraction: tumors beckon regulatory T cells. Nat. Med. (2004) 10(9) :900–901.
   PubMed Web of Science ®Google Scholar
• LEMAISTRE C, MENEGHETTI C, ROSENBLUM M et al: Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor. Blood (1992) 79(10):2547–2554.
   PubMed Web of Science ®Google Scholar
• WHERRY EJ, TEICHGRABER V, BECKER TC et al: Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat. Immunol (2003) 4(3):225–234.
   PubMed Web of Science ®Google Scholar
• BADOVINAC VP, PORTER BB, HARTY JT: CD8* T cell contraction is controlled by early inflammation. Nat. Immunol (2004) 5(8):809–817.
   PubMed Web of Science ®Google Scholar
• •Demonstrates that a CD8 * T cell memory can be generated in the almost complete absence of an effector response.
   Google Scholar
• DALE C, DE ROSE R, STRATOV I et al.:Efficacy of DNA and fowlpox virus priming/boosting vaccines for simian/human immunodeficiency virus. Virol (2004) 78(24):13819–13828.
   Web of Science ®Google Scholar
• SANTRA S, BAROUCH DH, KORIOTH-SCHMITZ B et al: Recombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory T lymphocyte responses. Proc. Natl. Acad. Sci. USA (2004) 101(30):11088–11093.
   PubMed Web of Science ®Google Scholar
• •Poxyirus boosting in primates fails to boost memory responses.
   Google Scholar
• MADAKAMUTIL LT, CHRISTEN U, LENA CJ et al: CD8aa-mediated survival and differentiation of CD8 memory T cell precursors. Science (2004) 304(5670):590–593.
   PubMed Web of Science ®Google Scholar
• ORAN AE, ROBINSON HL: DNA vaccines: influenza virus challenge of a Th2/Tc2 immune response results in a Th2/Tc1 response in the lung. J. Virol (2004) 78(8):4376–4380.
   PubMed Web of Science ®Google Scholar
• WOODBERRY T, GARDNER J, ELLIOTT SL et al: Prime boost vaccination strategies: CD8 T cell numbers, protection, and Thl bias. J. Immunol (2003) 170(5):2599–2604.
   PubMed Web of Science ®Google Scholar
• CHAPUT N, SCHARTZ NE, ANDRE F et al.: Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tel lymphocytes leading to tumor rejection. Immunol. (2004) 172(4):2137–2146.
   Google Scholar
• PARDOLL DM: Spinning molecular immunology into successful immunotherapy. Nat. Rev. Immunol. (2002) 2(4):227–238.
   PubMed Web of Science ®Google Scholar
• OVERWIJK WW, THEORET MR, FINKELSTEIN SE et al.: Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CM* T cells. J. Exp. Med. (2003) 198(4):569–580.
   PubMed Web of Science ®Google Scholar
• ••Demonstrates the stringent requirements for immune rejection of an established tumour.
   Google Scholar
• DUDLEY ME, WUNDERLICH JR, ROBBINS PF et al.: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 298(5594):850–854.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, YANG JC, RESTIFO NP: Cancer immunotherapy: moving beyond current vaccines. Nat. Med. (2004) 10(9):909–915.
   PubMed Web of Science ®Google Scholar
• WANG HY, LEE DA, PENG G et al.: Tumor-specific human CD4* regulatory T cells and their ligands: implications for immunotherapy. Immunity (2004) 20(1):107–118.
   PubMed Web of Science ®Google Scholar
• CURIEL TJ, COUKOS G, ZOU L et al.: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. (2004) 10(9):942–949.
   PubMed Web of Science ®Google Scholar
• •Links Treg in human cancer to poor prognosis, highlighting the importance of overcoming T,.eg suppression with cancer imunotherapies.
   Google Scholar
• LU W, WU X, LU Y, GUO W, ANDRIEU JM: Therapeutic dendritic-cell vaccine for simian AIDS. Nat. Med. (2003) 9(1):27–32.
   PubMed Web of Science ®Google Scholar
• TSCHARKE DC, KARUPIAH G, ZHOU J et al.: Identification of poxvirus CD8*T cell determinants to enable rational design and characterization of smallpox vaccines. J. Exp. Med. (2005) 201(1):95–104.
   PubMed Web of Science ®Google Scholar
• WHITMORE M: Synergistic activation of innate immunity by double-stranded RNA and CpG DNA promotes enhanced anti-tumor activity. Cancer Res. (2004) 64(16):5850–5860.
   PubMed Web of Science ®Google Scholar
• O'ROURKE MG, JOHNSON M, LANAGAN C et al.: Durable complete clinical responses in a Phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol. Immunother. (2003) 52(6):387–395.
   Google Scholar